These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 20637304)

  • 1. Vaccination with a chaperone complex based on PSCA and GRP170 adjuvant enhances the CTL response and inhibits the tumor growth in mice.
    Huo W; Ye J; Liu R; Chen J; Li Q
    Vaccine; 2010 Aug; 28(38):6333-7. PubMed ID: 20637304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
    Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
    J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endoplasmic reticulum chaperone glucose regulated protein 170-Pokemon complexes elicit a robust antitumor immune response in vivo.
    Yuan B; Xian R; Wu X; Jing J; Chen K; Liu G; Zhou Z
    Immunobiology; 2012 Jul; 217(7):738-42. PubMed ID: 22317751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.
    Garcia-Hernandez Mde L; Gray A; Hubby B; Klinger OJ; Kast WM
    Cancer Res; 2008 Feb; 68(3):861-9. PubMed ID: 18245488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
    Dannull J; Diener PA; Prikler L; Fürstenberger G; Cerny T; Schmid U; Ackermann DK; Groettrup M
    Cancer Res; 2000 Oct; 60(19):5522-8. PubMed ID: 11034097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gp100.
    Wang XY; Chen X; Manjili MH; Repasky E; Henderson R; Subjeck JR
    Cancer Res; 2003 May; 63(10):2553-60. PubMed ID: 12750279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells.
    Morgenroth A; Cartellieri M; Schmitz M; Günes S; Weigle B; Bachmann M; Abken H; Rieber EP; Temme A
    Prostate; 2007 Jul; 67(10):1121-31. PubMed ID: 17492652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel DNA vaccine constructed by heat shock protein 70 and melanoma antigen-encoding gene 3 against tumorigenesis.
    Qu P; Ma JH; Zhang XM; Huang XJ; Yang XW; Yan-Fang S
    Indian J Exp Biol; 2010 May; 48(5):436-43. PubMed ID: 20795360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human prostate stem cell antigen and HSP70 fusion protein vaccine inhibits prostate stem cell antigen-expressing tumor growth in mice.
    Dong L; Zhang X; Ren J; Wu S; Yu T; Hou L; Fu L; Yi S; Yu C
    Cancer Biother Radiopharm; 2013 Jun; 28(5):391-7. PubMed ID: 23701419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel DNA/peptide combined vaccine induces PSCA-specific cytotoxic T-lymphocyte responses and suppresses tumor growth in experimental prostate cancer.
    Zhang KQ; Yang F; Ye J; Jiang M; Liu Y; Jin FS; Wu YZ
    Urology; 2012 Jun; 79(6):1410.e7-13. PubMed ID: 22513035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
    Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
    J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens.
    Bleifuss E; Bendz H; Sirch B; Thompson S; Brandl A; Milani V; Graner MW; Drexler I; Kuppner M; Katsanis E; Noessner E; Issels RD
    Int J Hyperthermia; 2008 Dec; 24(8):623-37. PubMed ID: 18608582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts.
    Saffran DC; Raitano AB; Hubert RS; Witte ON; Reiter RE; Jakobovits A
    Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2658-63. PubMed ID: 11226295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chaperoning function of stress protein grp170, a member of the hsp70 superfamily, is responsible for its immunoadjuvant activity.
    Park JE; Facciponte J; Chen X; MacDonald I; Repasky EA; Manjili MH; Wang XY; Subjeck JR
    Cancer Res; 2006 Jan; 66(2):1161-8. PubMed ID: 16424054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens.
    Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
    Immunol Lett; 2005 Jun; 99(1):85-93. PubMed ID: 15894116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with tumor-derived ER chaperone grp170 elicits tumor-specific CD8+ T-cell responses and reduces pulmonary metastatic disease.
    Wang XY; Kazim L; Repasky EA; Subjeck JR
    Int J Cancer; 2003 Jun; 105(2):226-31. PubMed ID: 12673684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced multiepitope-based vaccines elicit CD8+ cytotoxic T cells against both immunodominant and cryptic epitopes.
    Tine JA; Firat H; Payne A; Russo G; Davis SW; Tartaglia J; Lemonnier FA; Demoyen PL; Moingeon P
    Vaccine; 2005 Jan; 23(8):1085-91. PubMed ID: 15620483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells.
    Dai S; Wan T; Wang B; Zhou X; Xiu F; Chen T; Wu Y; Cao X
    Clin Cancer Res; 2005 Oct; 11(20):7554-63. PubMed ID: 16243831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
    Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.